Technical Analysis for CVAC - CureVac N.V.

Grade Last Price % Change Price Change
B 115.4999 1.23% 1.40
CVAC closed up 1.03 percent on Thursday, April 22, 2021, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical CVAC trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 1.64%
NR7 Range Contraction 1.64%
NR7-2 Range Contraction 1.64%
Wide Bands Range Expansion 1.64%
Overbought Stochastic Strength 1.64%
NR7 Range Contraction 2.68%
Multiple of Ten Bullish Other 2.68%
Wide Bands Range Expansion 2.68%
Overbought Stochastic Strength 2.68%
Upper Bollinger Band Walk Strength 4.69%
Older End-of-Day Signals for CVAC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace 33 minutes ago
Rose Above Previous Day's High about 1 hour ago
Up 1% about 1 hour ago
Possible NR7 about 21 hours ago
Upper Bollinger Band Resistance about 23 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


CureVac N.V. Description

CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Acid Solid Tumors Health Care Coronavirus Vaccination Glaxosmithkline Pharmaceutical Companies CRISPR Rabies Sars Boehringer Ingelheim Arcturus Therapeutics Genmab

Is CVAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 151.8
52 Week Low 36.15
Average Volume 877,479
200-Day Moving Average 0.00
50-Day Moving Average 95.90
20-Day Moving Average 96.76
10-Day Moving Average 104.25
Average True Range 4.99
ADX 22.27
+DI 32.98
-DI 16.75
Chandelier Exit (Long, 3 ATRs ) 99.88
Chandelier Exit (Short, 3 ATRs ) 96.79
Upper Bollinger Band 116.74
Lower Bollinger Band 76.78
Percent B (%b) 0.93
BandWidth 41.31
MACD Line 5.49
MACD Signal Line 2.91
MACD Histogram 2.5766
Fundamentals Value
Market Cap 20.31 Billion
Num Shares 178 Million
Price-to-Sales 315.17
Price-to-Book 20.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 118.69
Resistance 3 (R3) 118.43 116.65 117.93
Resistance 2 (R2) 116.65 115.48 116.78 117.67
Resistance 1 (R1) 115.37 114.76 116.01 115.63 117.41
Pivot Point 113.59 113.59 113.91 113.72 113.59
Support 1 (S1) 112.31 112.42 112.95 112.57 110.79
Support 2 (S2) 110.53 111.70 110.66 110.53
Support 3 (S3) 109.25 110.53 110.28
Support 4 (S4) 109.51